Dec 21, 2023
Valcon Medical achieves milestone: First Danish-manufactured medical cannabis oil approved by the Danish Medicines Agency

Valcon Medical A/S, a Danish medical cannabis manufacturing company, disclosed a significant achievement. The Danish Medicines Agency (DKMA) has approved the inclusion of the first Danish-manufactured medical cannabis oil on the list of authorized medical cannabis products.

Read the article
Jul 31, 2023
The European Pharmacopoeia Commission (EPC) has adopted a new European monograph for Cannabis flower

The European Pharmacopoeia Commission has adopted a new European monograph for Cannabis flower at the latest Commission meeting in June 2023. The monograph describes quality requirements for the raw material Cannabis flower.

Read the article
Jun 15, 2023
Valcon Medical has reached another significant milestone with the successful implementation of a consistent supply chain to United Kingdom

In United Kingdom Medicinal Cannabis is classified as an unlicensed medicine/Specials and manufactured to meet a specific patient’s clinical needs. Valcon Medical offers exciting partnership opportunities for standardised cannabis oil brands in the United Kingdom.

Read the article
Mar 22, 2023
Valcon Medical is proud to announce its new partnership agreement with a well reputed Polish manufacturer of medicinal cannabis

Introduction of medicinal cannabis to the Polish market requires a marketing authorisation for a pharmaceutical raw material to prepare prescription drugs in the form of non-fibrous hemp herbs, extracts, and tinctures.

Read the article
Jan 23, 2023
Valcon Medical acquires Danish cannabis distributor and re-packer ScanLeaf ApS, extends product reach and capabilities

ScanLeaf’s market penetration, along with additional licensing, further strengthens Valcon’s position in the European Medical Cannabis market. Valcon Medical are excited to announce that they have completed the acquisition of Scanleaf ApS.

Read the article
Aug 25, 2022
Valcon Medical Announces First Dispatch of EU-Certified Medical Cannabis Extracts and Standardised Oils to Germany

The first dispatch of EU-certified medical cannabis extracts and standardised oils to Germany highlights Valcon Medical's poised to significantly impact the medical cannabis industry and the lives of chronic patients.

Read the article
May 9, 2022
ENEXIS makes an investment in Denmark-based medical cannabis group Valcon Medical

Valcon Medical Closes Series C Round and Launches Global Commercial Sales of Medical Cannabis Products - Funding led by Altitude Investment Management, Artemis Growth Partners, and Enexis AB, increases total capital raised to €11.8 million.

Read the article
Feb 19, 2022
Hasse Skovbo Knap is a scientific specialist in the company Valcon Medical – talent 100 Berlingske

Hasse Skovbo Knap is a scientific specialist at Valcon Medical, which was established due to the medicinal cannabis pilot programme that came into force in 2018. The company aims to extract oil from cannabis flowers grown in Denmark.

Read the article
Jul 1, 2021
Valcon Medical Granted Authorisation by The Danish Medicines Agency to Manufacture Cannabis Intermediate products for Danish Pilot Programme

Valcon Medical has a build a state-of-the-art manufacturing facility and rigorous quality control processes ensure the production of pharmaceutical-grade cannabis intermediate products, meeting the strict regulatory requirements set by The Danish Medicines Agency.

Read the article
Jul 1, 2021
Valcon Medical Granted Authorisation by The Danish Medicines Agency for Manufacturing Cannabis Bulk Extracts under the Pilot Programme

With the authorisation to manufacture cannabis bulk extracts under the pilot programme, the company will leverage its expertise to manufacture high-quality cannabis bulk extracts, ensuring strict adherence to regulations and guidelines.

Read the article
Jun 27, 2020
Valcon Medical granted authorisation by The Danish Medicines Agency for activities with euphoriant substances

Danish Medicines Agency has granted Valcon Medical the necessary approval to engage in activities related to euphoriant substances marking a significant milestone for and enforces its commitment to providing safe and effective treatments to chronic patients.

Read the article